Asia Pacific's largest biotech CRO Novell Health passed the Hong Kong Stock Exchange hearing. TPG and Sequoia are shareholders, and the target valuation may exceed 4 billion US dollars
According to previous reports, Novi Health will conduct a pre-roadshow this week. The company's target valuation exceeds 4 billion US dollars and is expected to raise 1.5 billion US dollars (about 11.65 billion Hong Kong dollars).
New share news | Novak Health is heard by the Hong Kong Stock Exchange, Q1 has a net loss of US $14.558 million in 2021
Novi Health Technology Holdings Co., Ltd. is a contract research organization specializing in serving biotechnology companies in the Asia-Pacific region.
No Data